Background: In regional and rural Australia, patients experiencing ischemic stroke do not have equitable access to an intravenous recombinant tissue plasminogen activator (tPA). Although thrombolysis with tPA is a clinically proven and cost-effective treatment for eligible stroke patients, there are few economic evaluations on pre-hospital triage interventions to improve access to tPA. Aim: To describe the potential cost-effectiveness of the pre-hospital acute stroke triage (PAST) protocol implemented to provide priority transfer of appropriate patients from smaller hospitals to a primary stroke center (PSC) in regional New South Wales, Australia. Materials and methods: The PAST protocol was evaluated using a prospective and historical cont...
Objective Stroke telemedicine improves the provision of reperfusion therapies in regional hospitals...
Background and Purpose—The aim of this study was to determine the cost-effectiveness of tissue-type ...
Background and Purpose—Intravenous tissue plasminogen activator (tPA) is an economically worthwhile ...
Background: In regional and rural Australia, patients experiencing ischemic stroke do not have equit...
BackgroundIn regional and rural Australia, patients experiencing ischemic stroke do not have equitab...
Introduction: Telemedicine can address limited access to medical specialists in rural hospitals. Str...
Introduction: Telemedicine can address limited access to medical specialists in rural hospitals. Str...
Background and Purpose: Level I evidence from randomized controlled trials demonstrates that the mod...
Objective: To assess the effectiveness of the PAST (Pre-hospital Acute Stroke Triage) protocol in re...
Background and Purpose-Thrombolytic therapy is licensed for use in highly selected patients with acu...
Rationale Access to intravenous thrombolysis for acute ischaemic stroke is limited worldwide, partic...
OBJECTIVES: While very early mobilisation (VEM) intervention for stroke patients was shown not to be...
OBJECTIVES: While very early mobilisation (VEM) intervention for stroke patients was shown not to be...
BACKGROUND AND PURPOSE: Thrombolysis in acute stroke is effective up to 4.5 hours after symptom onse...
Abstract- Purpose: This work was undertaken to review current evidence of cost-effectiveness analysi...
Objective Stroke telemedicine improves the provision of reperfusion therapies in regional hospitals...
Background and Purpose—The aim of this study was to determine the cost-effectiveness of tissue-type ...
Background and Purpose—Intravenous tissue plasminogen activator (tPA) is an economically worthwhile ...
Background: In regional and rural Australia, patients experiencing ischemic stroke do not have equit...
BackgroundIn regional and rural Australia, patients experiencing ischemic stroke do not have equitab...
Introduction: Telemedicine can address limited access to medical specialists in rural hospitals. Str...
Introduction: Telemedicine can address limited access to medical specialists in rural hospitals. Str...
Background and Purpose: Level I evidence from randomized controlled trials demonstrates that the mod...
Objective: To assess the effectiveness of the PAST (Pre-hospital Acute Stroke Triage) protocol in re...
Background and Purpose-Thrombolytic therapy is licensed for use in highly selected patients with acu...
Rationale Access to intravenous thrombolysis for acute ischaemic stroke is limited worldwide, partic...
OBJECTIVES: While very early mobilisation (VEM) intervention for stroke patients was shown not to be...
OBJECTIVES: While very early mobilisation (VEM) intervention for stroke patients was shown not to be...
BACKGROUND AND PURPOSE: Thrombolysis in acute stroke is effective up to 4.5 hours after symptom onse...
Abstract- Purpose: This work was undertaken to review current evidence of cost-effectiveness analysi...
Objective Stroke telemedicine improves the provision of reperfusion therapies in regional hospitals...
Background and Purpose—The aim of this study was to determine the cost-effectiveness of tissue-type ...
Background and Purpose—Intravenous tissue plasminogen activator (tPA) is an economically worthwhile ...